Sex and sniffles prove good for Reckitt
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Reckitt Benckiser thanked strong demand for cold and flu remedies and for Durex condoms for its 3 per cent rise in profits last year.
The consumer goods giant, which also makes Nurofen painkillers and Dettol disinfectant, beat City expectations as pre-tax profits edged up 2 per cent to £2.4bn after exceptional costs, mainly relating to restructuring, rose to £135m.
Reckitt said "higher incidences of cold and flu" had triggered a leap in demand for its Strepsils sore throat sweets and Mucinex chesty cough medicine in Europe and North America in the fourth quarter. And Durex's new Performax Intense condoms, plus expansion in China, had given the condom brand "a particularly strong quarter".
Rakesh Kapoor, who took over as chief executive from Bart Brecht in 2011, said: "We are now setting the target of … our emerging market areas to become 50 per cent of our core business net revenue by 2015."
Mr Kapoor forecast that sales this year would rise as much as 6 per cent, boosted by acquisitions. Reckitt bought a "modest-sized" traditional Chinese medicine company and earlier this week announced a $482m (£308m) deal with the US group Bristol-Myers Squibb to sell over-the-counter drugs in Brazil and Mexico.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments